Supplementary Material

David Wyllie ¹⁺ , Ranya Mulchandani ¹ , Hayley E Jones ² , Sian Taylor-
Phillips ³ , Tim Brooks ¹ , Andre Charlett ¹ , AE Ades ² , EDSAB-HOME
nvestigators, Andrew Makin ⁴ , Isabel Oliver ¹
+ correspondence: david.wyllie@phe.gov.uk
1 Public Health England
2 University of Bristol
3 University of Warwick
4 Oxford Immunotec Ltd
David Wyllie, Public Health England, Forvie Site, Addenbrookes' Campus,
Robinson Way, Cambridge, CB2 0SR.
P ir + 1 2 3 4 -

Table of Contents

Methods	4
Study participants	4
Laboratory Immunoassays	4
T-SPOT Discovery SARS-CoV-2 Testing	5
Masking	5
Endpoints used on follow-up	6
Statistics	7
Objective 1: Describe baseline immunological responses to the SARS-CoV-2 virus	7
Objective 2: Measure associations between baseline immunological responses and subsec	quent
COVID-19	8
Sample size calculations	9
References	10
Tables	11
Table S1: Reported Seroconversion rates in acute SARS-CoV-2 infection	11
Table S2: EDSAB-HOME Demographics and exposure characteristics	
Table S3: Peptide panel results reported	15
Table S4: Categorisation of EuroImmun anti-Spike IgG index	16
Table S5: Responses to different peptide panels	17
Table S6: Risk factors for high SNM T-SPOT results when seronegative	17
Table S7: Continuous exposure variables: primary and sensitivity analyses	
Figures	20
Figure Legends	21
Figure S1: Outbreak in the UK and its relationship to follow-up	21
Figure S2: Patterns of serological responses seen	21

Figure S3: Correlations between responses to different SARS-CoV-2 components	21
Figure S4: SNM T-SPOT results compared with anti-Nucleoprotein antibody	21
Figure S5: SNM responsive T cell numbers in individuals with previous positive PCR tests	21
Figure S6: Selection of cohorts at high and low risk of previous SARS-CoV-2 infection	22
Figure S7: ROC analysis separating low risk individuals from those with past infection	22

Methods

Study participants

We studied participants in the EDSAB-HOME study (1), which recruited three key worker "streams". Two streams (Streams A, B) comprised Fire & Rescue or Police service key workers, or Health care key workers (n=1,139, n=1,533 respectively), independent of any history of COVID-19 disease or RT-PCR testing; for Stream C, a history of prior RT-PCR positive testing was required (n=154). The cohorts did not include acutely infected individuals; among the 268 (9.4%) cases who had had a prior positive RT-PCR result, the test had occurred a median of 63 days prior to recruitment. Recruitment occurred in June 2020. All participants provided written informed consent.

Individuals who were currently working at their place of work, or eligible to do so, aged 18 years or over, able to read English and to provide informed consent were eligible to enrol, as described (<u>ISRCTN56609224</u>). Anyone currently experiencing COVID-19 compatible symptoms, who had experienced any in the last 7 days, meeting the UK Government's criteria for "exceptionally vulnerable", or taking part in any COVID-19 vaccine trials was ineligible.

Participants completed an online questionnaire prior to clinic attendance. On attending a study clinic, venous blood samples were taken from each participant. Each subject had a 6ml blood sample anticoagulated using EDTA, plasma was separated by centrifugation and stored at -80°C until use and 6ml (for the first 500 participants) or 10ml (thereafter) of blood anticoagulated with lithium heparin, stored at room temperature and shipped overnight to Oxford Immunotec (Milton Park, Oxon, UK) for T-SPOT[®] *Discovery* SARS-CoV-2 tests.

Laboratory Immunoassays

We characterised serological responses against SARS-CoV-2 using two commercial immunoassays: Roche Elecsys[®] anti-SARS-CoV-2 (2), and EUROIMMUN anti-S IgG immunoassays (1). We report the association between protection and the EUROIMMUN assay in this paper. Results failing immunoassays for technical reasons were repeated, as per normal clinical practice, and samples with insufficient volume for testing were excluded from analyses. We considered these assays positive if the Roche Elecsys[®] immunoassay signal was over 1.0, as recommended by the manufacturer, or the EUROIMMUN immunoassay index was over the 'confirmed' cutoff of 1.1 (1).

T-SPOT Discovery SARS-CoV-2 Testing

In brief, cells were purified from peripheral blood and SARS-CoV-2 responsive T cell numbers quantitated using a T-SPOT Discovery SARS-CoV-2 tests, which are based on the same proven analytical platform as the T-SPOT[®]. *TB* (tuberculosis) kit also produced by Oxford Immunotec.

In detail, peripheral blood mononuclear cells (PBMCs) were isolated from a whole blood sample using T-Cell Select reagent (Oxford Immunotec). The T-Cell Select kit contains a proprietary set of reagents consisting of buffer concentrate, antibodies, and superparamagnetic beads. Diluted T-Cell Select buffer is added to the whole blood sample to facilitate cell purification and reduce red blood cell contamination, and then antibodies are added which bind to the requisite immune cells in the sample. Cell separation was done using a validated automated platform, with a KingFisher magnetic separator (ThermoFisher). Cells were resuspended, counted using Guava flow cytometers (Luminex Corp), and following dilution 250,000 peripheral blood mononuclear cells per well were processed using T-SPOT Discovery SARS-CoV-2 tests, incubated for 16-20 hours at 37 degrees. Seven wells were used for each sample- 1. Nil Control to identify non-specific cell activation, Panels 2-6 SARS-CoV-2 specific antigen panels and Panel 7- Positive Control: Mitogen solution containing phytohaemagglutinin (PHA) to confirm PBMC functionality (Table S3). A second antibody, conjugated to alkaline phosphatase and directed to a different epitope on the cytokine molecule, is added and binds to the cytokine captured on the membrane surface. Any unbound conjugate is removed by washing. A soluble substrate is added to each well; this is cleaved by bound enzyme to form a spot of insoluble precipitate at the site of the reaction. Spots were read using automated cell counting equipment (CTL, Immunospot). The protocol followed the manufacturer's instructions exactly.

A sample was considered indeterminate if a) the Nil Control spot count was in excess of 6 spots per 250,000 PBMCs or b) the Positive Control well containing phytohemagglutinin (PHA) had less than 20 spots.

Masking

None of the individuals who ran the laboratory immunoassays, either serological or T-SPOT, had access to any information about the samples. The only exception is with the 154 Stream C samples. Stream C recruited after Streams A and B, and only contained PCR positive individuals. Laboratory staff knew this prior to sample receipt. All laboratory immunoassays were completed prior to any data

analysis. Participants were made aware of their EUROIMMUN serological results approximately one month after their clinic visit, with a warning this was not indicative of protection from disease. Participants were not informed of their Roche or T-SPOT results. We derived the T-SPOT cutoff value, separating individuals with higher vs. lower SARS-CoV-2 responsive T cell numbers, based on separation of individuals with known SARS-CoV-2 infection vs. a low risk cohort; this activity preceded analysis of follow-up data.

Endpoints used on follow-up

The endpoint was having a SARS-CoV-2 RT-PCR positive test at least 12 days after recruitment.

For participants symptom driven testing was available without charge through state and employer routes. National criteria operate for obtaining such tests; these require at least one of a persistent cough, fever, or a change of taste or smell¹. Asymptomatic screening of contacts operated in some workplaces from 6 November 2020, in response to outbreaks. Nationally, SARS-CoV-2 RT-PCR test results are gathered by Public Health England (PHE)'s Second Generation Surveillance System (SGSS) with laboratory reporting by this route is required by law. Participants consented to national data systems being searched for their records.

Participants were matched using National Health Service (NHS) number (a unique identifier used by the NHS to identify all registered individuals). For 87% of participants, we were able to look up NHS numbers, which are not widely known by UK residents, by Demographics Batch Searches against NHS data systems. In all cases, we additionally performed searches based on surname, forename and data of birth to maximise ascertainment of SARS-CoV-2 RT-PCR results.

We performed additional checks on individuals with a positive endpoint as follows:

- All positive results were reviewed manually and correct matching assured using geographic or and any other identifiers unused in the initial match.
- Where available, the contemporaneous recorded symptom noted by the participant was checked. A proportion of volunteers agreed on recruitment to perform weekly symptom diaries. This was optional, and volunteers could opt out.

¹ <u>https://www.nhs.uk/conditions/coronavirus-covid-19/testing-and-tracing/get-a-test-to-check-if-you-have-coronavirus/</u> accessed 10 October 2020

All participants with positive tests were sent an optional post-positive test questionnaire. This
asked about symptoms and circumstances around the test.

For survival analysis, we started follow-up 12 days after the recruitment clinic visit, to avoid inclusion of individuals who may have been incubating infection at the clinic visit. This resulted in the exclusion of one individual only, who developed disease 5 days after recruitment. For the logistic regression analysis, we started follow-up on 8 July 2020, which is 12 days after the last participant was recruited.

Various national surveillance projects (such as those run by the Office for National Statistics², and the REACT1 study³), do offer tests to UK citizens. We excluded one individual with chronic post-COVID-19 symptoms who took such a test without any change in their symptoms. The individual was notified of the test result, which was positive, by the national surveillance project; the participant contacted the EDSAB-HOME study team to discuss this result as they (and we, subsequently) were unclear as to its interpretation. It may reflect a false positive test.

In late Sept-2020, a second wave of infection was beginning in England; for detail, see: https://coronavirus.data.gov.uk/ and Figure S1.

Statistics

Objective 1: Describe baseline immunological responses to the SARS-CoV-2 virus

To explore and depict individuals' multi-dimensional immunological results (T-SPOT counts to six pools of peptides; immunoassay results), we performed hierarchical clustering, displaying results as heatmaps. In doing so, we transformed T-SPOT responses generating log₁₀ (number of cells per 250,000 + 1), and transformed serological indexes (the raw value reported by the immunoassay) as log₁₀ (immunoassay signal). This data was then clustered based on Minkowski distances using hierarchical clustering using Ward's method (4). Data were depicted using the R *hclust* function. In some analyses, we report the sum of T-SPOT responses to groups of wells, subtracting the background, see Supplementary Material Table S3. Comparing T-SPOT responses in two groups of

2

https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/ methodologies/covid19infectionsurveypilotmethodsandfurtherinformation accessed 10 Sept 2020 ³ https://www.imperial.ac.uk/medicine/research-and-impact/groups/react-study/ accessed 10 Sept 2020

individuals was done using Wilcoxon Ranked-sign tests, and more than two groups used Kruskal-Wallis tests.

To depict associations between immunological and clinical metadata (see Table S2), we computed Spearman correlation coefficients ρ , regarding ρ different from 0 if the associated *p* value was less than 0.01, adjusted for multiple comparisons using Bonferroni's method, depicting correlations as heatmaps.

To analyse the T-SPOT result of individuals, we computed the sum of T-SPOT responses to groups of panels, subtracting the background (Table S3). T-SPOT values optimally separating 154 individuals with high vs. 1087 individuals at low risk of past infection were computed (see Supp. Methods Fig. S6) using Youden's method (37). The high risk individuals had had previous positive RT-PCR tests. The low risk individuals reported no personal or household symptoms compatible with COVID-19 since January 2020, had had no positive RT-PCR tests, and had negative anti-Spike and anti-Nucleoprotein immunoassays using stringent cutoffs (index less than 0.35 for both assays).

Objective 2: Measure associations between baseline immunological responses and

subsequent COVID-19

To determine whether T-SPOT results or anti-Spike IgG concentrations (immunological predictors) were associated with protection from COVID-19, we started follow-up 12 days after the last recruitment (i.e. 8 July 2020), so subjects were followed for the same time. We did this to avoid inclusion of individuals who may have developed immune responses prior to symptom recognition, choosing the 12 day cutoff because only about 2.5% of cases have incubation periods longer than 11.5 days(38). Two endpoints were excluded on these grounds (see also Supplementary Materials).

We first quantified univariable associations between a number of baseline factors, including categorised antibody index (Table S4) and T-SPOT response. We similarly divided and analysed T-SPOT SNM responses. To quantify effect sizes, we used univariable and multivariable Poisson regression models including age (as a continuous variable), gender, high risk occupation (defined as being medical or nursing hospital staff), ethnicity (white vs. non-white) as well as (for time-to-event analyses) the average incidence (individuals testing positive in the last 7 days) in the NHS region of residence of the participant included as a time-dependent covariate. We also included T-SPOT

response and EuroImmun anti-Spike IgG assay result. In some analyses, we used categorisations of these (as above), and in others we modelled these as continuous variables. When modelling EuroImmun antibody indexes as continuous variables, we recoded values of over 10 as 10, as values over 10 indicate assay saturation. We then subtracted 0.35 from the variables, recoding negative values as zero, because we regard values less than 0.35 as representing technical assay background, with which disease risk is not expected to alter (see Results). We modelled square root transformed EuroImmun anti-Spike IgG index and square root transformed T-SPOT SNM responses, after selecting suitable transformations from linear, square root, log transform, 3 and 5 knot cubic splines using visual linearity and homoscedasticity assessment (by assessment of residuals), as well as Bayesian information criteria (BIC). In sensitivity analyses, we also used log transformations.

Analyses used R 4.0.2 or (for Poisson regression) Stata 16 for Windows.

Sample size calculations

Study size was aimed to achieve narrow confidence intervals around the performance of antibody detection tests, as described in the trial protocol (ISRCTN56609224).

References

1. Mulchandani R, Taylor-Phillips S, Jones H, Ades T, Borrow R, Linley E, et al. Self assessment overestimates historical COVID-19 disease relative to sensitive serological assays: cross sectional study in UK key workers. 2020:2020.08.19.20178186.

2. Evaluation of sensitivity and specificity of four commercially available SARS-CoV-2 antibody immunassays. Public Health England; 2020.

3. Hollander M, Wolfe D. Nonparametric statistical methods. New York: John Wiley & Sons; 1973. p. 185-94.

4. Everitt BS, Landau S, Leese M. Cluster Analysis: Wiley Publishing; 2009.

5. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine. 2020;26(6):845-8.

6. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. The New England journal of medicine. 2020.

7. Seow J, Graham C, Merrick B, Acors S, Steel KJA, Hemmings O, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. 2020:2020.07.09.20148429.

8. Luo YR, Chakraborty I, Yun C, Wu AHB, Lynch KL. Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity. 2020:2020.07.30.20165522.

9. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. The Cochrane database of systematic reviews. 2020;6(6):Cd013652.

Tables

Table S1: Reported Seroconversion rates in acute SARS-CoV-2 infection

ND, not determined.

Reference	Cohort	Seroconversion	Seroconversion	Seroconversion
		estimate: Roche	estimate: EUROIMMUN	estimate: other
		SARS-CoV-2 N protein	SARS-CoV-2 S1 protein	assays
		immunoassay (95%	immunoassay (95% CI)	
		CI)		
(2)	536 positive samples from	97.2% (95% CI 95.4 to	-	ND
	unique adult individuals with	98.4)		
	laboratory-confirmed SARS-			
	CoV-2 infection at ≥20 days			
	post-symptom onset.			
	Predominantly hospitalised.			
(1)	268 key workers with	96.6% (95% CI 93.7%	Eurolmmun: 93.3%	ND
	laboratory-confirmed SARS-	to 98.2%)	(95% CI 89.6% to	
	CoV-2 infection median 63		95.7%)	
	days post-symptom onset.			
	Predominantly community			
	(10% hospitalised)			
(5)	285 hospitalised COVID-19	ND	ND	100% > 20 days after
	cases			infection
(6)	34 cases, 30 PCR confirmed,	ND	ND	Measured responses
	32/34 were mild			against RBD (part of
				S1). 100%, but
				decline noted
(7)	65 hospitalised COVID-19	ND	ND	100% > 20 days after
	cases			infection, but decline
				noted
(8)	168 hospitalised COVID-19	ND	ND	100%; avidity
	cases			maturation noted
(9)	Systematic review, n=8,256.	ND	ND	96% (90-98%) for
	Cases mostly hospitalised			combined IgG/IgM at
				d 30 +

	Stream A: Police and Fire	Stream B: Healthcare	Stream C: HCW	Total
	and Fire			
		workers (HCW)	Previously	
			Positive	
			(HCW-PP)	
Age (years)				
18 – 25	37 (3.2%)	89 (5.8%)	13 (8.4%)	139 (4.9%)
25 - 40	420 (36.6%)	586 (37.9%)	62 (40.3%)	1068 (37.5%)
40 - 60	660 (57.5%)	747 (48.3%)	71 (46.1%)	1478 (51.9%)
60+	30 (2.6%)	124 (8.0%)	8 (5.2%)	162 (5.7%)
Gender				
Female	455 (39.7%)	1247 (80.7%)	126 (81.8%)	1828 (64.2%)
Male	692 (60.3%)	299 (19.3%)	28 (18.2%)	1019 (35.8%)
Ethnicity				
White	1085 (94.6%)	1128 (73.0%)	137 (89.0%)	2350 (82.5%)
Asian or British Asian	33 (2.9%)	237 (15.3%)	11 (7.1%)	281 (9.9%)
Black or Black British	2 (0.2%)	96 (6.2%)	1 (0.6%)	99 (3.5%)
Mixed	21 (1.8%)	42 (2.7%)	3 (1.9%)	66 (2.3%)
Other	6 (0.5%)	43 (2.8%)	2 (1.3%)	51 (1.8%)
Occupation				
First responder – police	528 (46.0%)	0 (0.0%)	0 (0.0%)	528 (18.5%)
First responder – fire & rescue	238 (20.7%)	0 (0.0%)	0 (0.0%)	238 (8.4%)
First responder – other (e.g. ambulance)	40 (3.5%)	1 (0.1%)	0 (0.0%)	41 (1.4%)
Hospital doctor	0 (0.0%)	245 (15.8%)	41 (26.6%)	286 (10.0%)
Hospital nurse	1 (0.1%)	471 (30.5%)	51 (33.1%)	523 (18.4%)
Hospital medical other	0 (0.0%)	249 (16.1%)	18 (11.7%)	267 (9.4%)
Hospital non-medical	0 (0.0%)	158 (10.2%)	9 (5.8%)	167 (5.9%)
Hospital lab based	0 (0.0%)	35 (2.3%)	1 (0.6%)	36 (1.3%)
GP doctor/nurse/other	0 (0.0%)	20 (1.3%)	4 (2.6%)	24 (0.8%)
Community nurse	0 (0.0%)	36 (2.3%)	9 (5.8%)	45 (1.6%)
NHS staff other	0 (0.0%)	309 (20.0%)	20 (13.0%)	329 (11.6%)
Other	340 (29.6%)	22 (1.4%)	1 (0.6%)	363 (12.8%)

Table S2: EDSAB-HOME Demographics and exposure characteristics

Interacted face-to-face with patients and/or				
general public during lockdown (post-23 March				
2020)				
More frequently than before lockdown	24 (2.1%)	161 (10.4%)	13 (8.4%)	198 (7.0%)
Similar to before lockdown	494 (43.1%)	671 (43.4%)	91 (59.1%)	1256 (44.1%)
Less frequently than before lockdown	418 (36.4%)	564 (36.5%)	40 (26.0%)	1022 (35.9%)
No such interactions	39 (3.4%)	28 (1.8%)	2 (1.3%)	69 (2.4%)
Non-response	172 (15.0%)	122 (7.9%)	8 (5.2%)	302 (10.6%)
Do you think you have had previous COVID-19?				
Yes, I had symptoms but was not tested	225 (19.6%)	301 (19.5%)	0 (0.0%)	526 (18.5%)
Yes, I had symptoms but my test(s) were all	41 (3.6%)	112 (7.2%)	0 (0.0%)	153 (5.4%)
negative				
Yes, I had symptoms, and I had at least one positive	24 (2.1%)	80 (5.2%)	152 (98.7%)	256 (9.0%)
test				
Yes, I had symptoms, had a test, but it failed	5 (0.4%)	3 (0.2%)	0 (0.0%)	8 (0.3%)
I did not recognise that I had symptoms, but I tested	0 (0.0%)	10 (0.6%)	2 (1.3%)	12 (0.4%)
positive when I was screened				
No	557 (48.6%)	648 (41.9%)	0 (0.0%)	1205 (42.3%)
Unsure	295 (25.7%)	392 (25.4%)	0 (0.0%)	687 (24.1%)
Length of symptoms*				
Less than 7 days	115 (39.1%)	178 (36.1%)	30 (19.7%)	323 (34.4%)
7 -14 days	121 (41.2%)	185 (37.5%)	63 (41.4%)	369 (39.3%)
14 – 21 days	27 (9.2%)	66 (13.4%)	27 (17.8%)	120 (12.8%)
More than 21 days	28 (9.5%)	58 (11.8%)	30 (19.7%)	116 (12.4%)
Do not know	3 (1.0%)	6 (1.2%)	2 (1.3%)	11 (1.2%)
Unable to work (in workplace or at home) due to				
symptoms*				
Yes	191 (65.0%)	350 (71.0%)	144 (94.7%)	685 (72.9%)
No	103 (35.0%)	143 (29.0%)	8 (5.3%)	254 (27.1%)
Went to hospital due to suspected/confirmed				
COVID-19*				
Yes	4 (1.4%)	19 (3.9%)	15 (9.9%)	901 (96.0%)
No	290 (98.6%)	474 (96.1%)	137 (90.1%)	38 (4.0%)
Was in contact with a suspected or confirmed				
case in the 14-day prior to symptom onset*				
Yes, confirmed	23 (7.8%)	153 (31.0%)	92 (60.5%)	485 (51.7%)
Yes, suspected	47 (16.0%)	113 (22.9%)	26 (17.1%)	268 (28.5%)

No/Unsure	224 (76.2%)	227 (46.0%)	34 (22.4%)	186 (19.8%)
Has had a SARS-CoV-2 antibody test, and been				
informed of the result prior to recruitment				
Yes	4 (0.3%)	20 (1.3%)	68 (44.2%)	92 (3.2%)
No	1143 (99.7%)	1523 (98.5%)	86 (55.8%)	2752 (96.7%)
Did not answer	0 (0.0%)	3 (0.2%)	0 (0.0%)	3 (0.1%)
Had a household member who had COVID-19				
compatible symptoms				
Yes	289 (25.2%)	396 (25.6%)	83 (53.9%)	768 (27.0%)
No	858 (74.8%)	1150 (74.4%)	71 (46.1%)	2079 (73.0%)
Had a household member who had SARS-CoV-2				
positive nasal or throat swab				
Yes	21 (1.8%)	44 (2.8%)	32 (20.8%)	97 (3.4%)
No	1126 (98.2%)	1502 (97.2%)	122 (79.2%)	2750 (96.6%)
Total	1147	1546	154	2847

*for only those who self-reported COVID-19 compatible symptoms. In addition, variables where the participant did not respond (NAs) amongst those who reported symptoms were not included (1 in Police and Fire and 3 in HCW). Final total was 939, split across Police and Fire (n=295), HCW (n=496) and HCW-PP (n=152).

Table S3: Peptide panel results reported

Details of the peptide panels in the T-SPOT *Discovery* SARS-CoV-2 test

	Response to	Reported
Panel 1	S1 Spike domain	Observed cell number per
		250,000 PBMC
Panel 2	S2 Spike domain	Observed cell number per
		250,000 PBMC
Panel 3	Nucleoprotein	Observed cell number per
		250,000 PBMC
Panel 4	Matrix protein	Observed cell number per
		250,000 PBMC
Panel 5	Structural peptides	Observed cell number per
		250,000 PBMC
Panel 6	Envelope	Observed cell number per
		250,000 PBMC
Control	No peptide added	Observed cell number per
		250,000 PBMC
SNM	S antigen, Nucleoprotein and	(Panel1 + Panel 2 + Panel 3 +
	Matrix protein	Panel 4) – 4(Control), or zero
		is less than zero
ESTR	Envelope and structural	(Panel 5 + Panel 6) –
	proteins	2(Control), or zero if less than
		zero

Table S4: Categorisation of EuroImmun anti-Spike IgG index

Eurolmmun anti-SARS-CoV-2	Category referred to as	Comment
Spike S1 domain IgG		
immunoassay index		
0 <= index < 0.35	Seronegative	Cutoff is based on comparison
		with pre-pandemic sera, see
		results
0.35 <= index < 1.1	Weak reactivity	1.1 cutoff corresponds to the
		manufacturer's recommended
		'confirmed positive' cutoff
1.1 <= index < 3	Low level seropositive	About 30% of the EDSAB-
		HOME cohort with results > 1.1
		have results in this range, see
		results
Index >=3	High level seropositive	

				anti-Sc	oike inde	ex < 1.1			anti-Sp	oike inde	ex >= 1.3	1	Wilcoxon test
					n=2,264					-log ₁₀ (p)			
					Centiles	5				Centile	S		
	Response to	Note	5%	25%	50%	75%	95%	5%	25%	50%	75%	95%	
Panel 1	S1 Spike domain	1	0	0	1	2	6	1	3	7	14	39	170.9
Panel 2	S2 Spike domain	1	0	0	2	3	11	1	4	6	12	33	129.3
Panel 3	Nucleoprotein	1	0	0	1	3	8	1	6	12	23	59	200.0
Panel 4	Matrix protein	1	0	0	1	3	7	0	3	6	13	37	132.6
Panel 5	Structural peptides	1	0	0	1	2	4	0	0	1	3	7	12.0
Panel 6	Envelope	1	0	0	1	2	6	0	0	1	2	6	0.1
Cont- rol	No peptide added	1	0	0	0	1	3	0	0	0	1	3	0.5
SNM	S antigen, Nucleoprotein and Matrix protein	2	0	1	3	8	26	7	17	34	61	142	211.5
ESTR	Envelope and structural proteins												3.5
	structural proteins	3	0	0	1	3	8	0	0	1	3	9	

Table S5: Responses to different peptide panels

Note: metric reported is

- 1. Observed cell number per 250,000 PBMC
- 2. (Panel1 + Panel 2 + Panel 3 + Panel 4) 4(Control), or zero is less than zero
- 3. (Panel 5 + Panel 6) 2(Control), or zero if less than zero

Table S6: Risk factors for high SNM T-SPOT results when seronegative

SNM T cell responses per 250,000 PBMC, measured by the T-SPOT® *Discovery* SARS-CoV-2 test in EDSAB-HOME participants, stratified by anti-Spike IgG serostatus as well as clinical and immunological features.

								1																			
				All	particip	ants (n=	2,826)	Euro	Eurolmmun anti-Spike IgG index < 1.1 (n=2,264)				Seronega	ative par	ticipants: < 0.3	Eurolm 5 (n=2,	mun ant 172)	-Spike I	gG index	Eurolmr	nun anti-	Spike Ig	G positiv	e (index	>= 1.1)	(n=562)	
	SARS-CoV-2 risk factor	A -		-SPOT S	NM respo	rise centile:	s Kruskal-Wallis	т	-SPOT SI	NM respon	nse centik	s Krusk	al-Walls	T	SPOT SNN	1 response ce 25% Me	ntiles			iruskal-Wallis	т	SPOT SNN	I response o	entiles	75%	к	ruskal-Wallis
Demographics	Self-reported Ethnicity	Asian or Asian British Black or Black British	280	0	1	5 16	95% -log ₁₀ (p) 65 0.0	210	0 0	3 3	6.75		(p) 1.26	n 201 62	5%	0	dian 3	75% 6	95% - 20	09 ₁₀ (p) 1.27	n 70 34	5% 5.45	25% M	32.5	56.25	95% -l 215.5	og _{io} (p) 0.03
		Mixed Other	99 66 50	0 0 0	2	6 18 6 18 .5 14.75	69 - 62 - 64 -	65 51 39	0 1	1 4	8	15.8 - 22.5 - 28.2 -		49 38	0	0	4	7.75 7 8.5	15.95 13.8 28.3		34 15 11	6.95 9.2	15.25 21.5	29.5 37 33	61.5 56.5 61.5	124.05 109.3 108.5	
		White	2331	0	1	5 14	66 -	1899	0 1	1 3 1 4	8	27 -		1822	0	1	3	8	23.95		432	8	18 18	34	62	139	
	Occupation	Community nurse/other First responder - Fire & Rescue First responder - other	45 236 41	0	1	3 8	111 10.9 41 -	37 224 37	0 0	1 3	7	31.4 25.85 -	0.46	36 216	0	0	3	7.5	20.25 24.25	0.42	8	12.2 3.85	35.75 18.5	58 44	124.5 68.75	204.3 122.25	0.74
		First responder - other First responder - Police GP doctor/nurse/other	41 522 24	0 0 0 1.2	1	5 13 4 11 .5 19	42 - 43 - 126 -	37 462 17	0 1	4		29 - 25 - 16.2 -		36 448 17	0	1.75 1 0	4	10 9	22.25 25		4 60	15.3 4.9 18	16.5 15.75 40.5	78.5 29 62	143.75 48.5 110	152.75 92.35 245	
		Hospital Doctor Hospital Lab Based	286 35	0 2.	25 7	5 29	89 - 71 -	188	0 0	1 4	8	16.2 · 37.95 · 17.75 ·		173 24	0	0	3 3.5	7	16.2 25.8 17.85		98	3.4	40.5 19 7	32	59.25 62	245 221.35 98.6	
		Hospital Medical Other (Clinical Academic, Clinical Hosp)	261			6 16	65 -	204	0 1.25	5 3.5 1 4		27.55 -		194	0	1.75	3.5	8.5	17.85		57	3.4 8.8	16	37	55	99.4	
		Hospital Non-Medical (Maintenance,													0			8									
		Catering, Portering) Hospital Nurse NHS staff other	166 520 327	0	2	4 17 7 21.25 6 19	71 - 71 - 89 -	133 365 239	0 1) 3 1 3 1 3	8	25.8 - 29.8 - 24.1 -		130 346 232	0	0	2.5	6.75	23.65 25.75 22.45		33 155 88	9 6 6.35	23 14.5 18.75	45 29 38.5	67 51.5 70.5	139.2 120.2 161.5	
	Cander	Other	363	0	1	4 9	37 -	332	0 1	1 3	6.25	18 -		320	0	1	3	6	17		31	10.5	18.5	37	58	138	
	Age, categorised	female male 18-25	1816 1010	0	1	5 16 5 13 7 15.25	71 1.8 60 -	843	0 1	1 4	8	28 24 -	0.35	1367 805	0	1	3	7	23 22.8	0.84	395 167 40	6 7	17.5 17	35 33	62 60 40	139 154.4	0.06 4.99
	Age, categorised	18-25 26-40 41-60	136 1066			6 16.75			0 1	1 5	9	28.4 -	6.32	91 818	0	1	4	10.5 9	28.5 27	7.56	213	4.95	8.75 16	19.5 31	51	100.5 95.4	4.99
		41-60 >60	1466 158	0		4 13 4 13.75	77 - 86 -	1194 121	0 1	1 3 1 3	7	21 - 15 -		1148 115	0	1	3 2	6 5	18 13.6		272 37	8 8.6	20 23	38 45	74 77	164.25 141.6	
	Previous positive PCR test	No Yes	2558 268	0 8 21		4 11 5 67		2241 23	0 1	1 3		25 78.4 -	10.50	2166	0	1	3 8.5	7 24.75	23 36.75	0.14	317 245	5	15 21	28 42	54 69	128.4 183	4.97
		Not applicable - was not il	695	0		3 8		671	0 1			23.5	1.27	651	0	1	3	7	22	0.31	24	1.3	12.75	28	38.25	80.7	2.72
	Missed work with COVID-19 like illness	Yes, I was unable to work at all (either at workplace or from home)	912	-		0 36.25		531	0 1			38 -	1.21	499	0	1	4	,	25	0.54	381	7	19	38	67	153	2.72
	*** (ER33	No, but I worked from home No. I carried on as usual	912 135 1037		2	6 15		104 915	0 1.75	5 4	7.25	38 - 18 - 25.3 -		499 98 881	0	2	4 4 3	7	25 18 23		381 31 122	8	19 15 14	38 25 29	52.5 45.75	153 129.5 122.8	
		No, I carned on as usual I am not sure/cannot remember	1037 47	0	0	4 10 4 10.5	44 - 25 -	915 43	0 0	. 4) 3	8 8.5	25.3 - 24.3 -		881 43	0	0	3	8.5	23 24.3		122	0.75	14 3.75	29 14.5	40.75	122.8 27.4	
Household	Number of people in the household	1 2	238 820	0		6 12.75 5 16	68 0.8 67 -	0 192 648	0 1	1 4		23.45	1.04	182 629	0	1	4	7.75	17.95 24	0.12	46 172	8	18 17	35 37	62 60.25	135.25 130.8	0.35
	- AND THE REAL PROPERTY OF	3	670 786			5 16 5 14 5 14	67 · 69 · 62 ·	543 640		1 4	8	25 - 29.9 - 26 -		512 617	0	1 0	3	7	24 24.45 22.2		172 127 146	7.3 6.25	17 21 16.25	37 33 36	67.5 59.75	130.8 159 126.75	
		4 5 six or more	786 230 82		2	5 14 5 15 7 15	62 - 56 - 83 -	640 180 61	0 2			26 - 27.15 - 12 -		617 172 60	0	2	4	7	22.2 22.45 12.5		146 50 21	6.25	16.25 15 16	36 28 39	59.75 40.75 71	126.75 123.3 194	
		0		0 2					0 1	4	8				0	1	4	8				8	16				
	Number of children in the household	1	1534 523 600	0 0 0	2	5 16 5 13 4 14	73 0.9 57 - 62 -	1204 435 492	0 1	1 3 1 4 0 3		26 25.3 - 26 -	0.98	1153 416 475	0	1 1 0	3 4	8	23 22 23	0.19	330 88 108	6 8 6.35	18 15 17.75	35 31 33.5	62 57.5 62	141.55 138.65 178.35	0.13
		3	134 30	0 2.	25	4 14 6 12 6 15.75	59 -	492 106 22	0 1.25	5 4		28.75 -		4/5 101 22	0	1	4	7	23 17 21.45		108	6.35 8 15	17.75	28 36.5	46.5 65.75	178.35 112.65 157.25	
		5 or more	30 5	2.2	3	6 15.75 3 7	24 -	5	2.2 3	1 4 3 3		23.8 -		5	2.2	3	3	7.75	23.8		0	15	15.75	36.5	65.75	157.25	
	Household COVID-19 disease beliefs	Yes, they had symptoms but they were not te	568		2 6		78 16.3	397	0 1	1 3		28	0.20	376	0	1	3	7	21.25	0.73	171	6	18	35	58.5	160	0.57
		Yes, they had symptoms but their test(s) wer Yes, they had symptoms and they had at least	88 85	1	8 2	5 17.25 6 53	135 -	28	0 1		9.25			68 24	0.15	1 2	3.5 3	7	19.3 24.9		16 57	8.25 12.2	20.5 21	39 42	60.25 71	110.25 213.8	
		Yes, they had symptoms and had a test, but i Yes, they did not recognise that they had any	11	1 4	.5	8 18.5		3 5	0.4 2		6	71.6 9.2		2 5	3.1 0.4	3.5 2	4	4.5 6	4.9 9.2		3 6	5.6 7.25	8 10.5	11 18.5	68.5 25.75	114.5 43	
		No I am not sure / would not know	1685 383	0	1	4 11 5 15	51 · 69 ·	1446 313	0 1	1 3 1 4	8	25 29		1394 303	0	1	3 4	8 9	23 24.8		239 70	6 9.45	16 15	33 33	61 68	130.3 143.75	
Personal symptoms	Believes has had COVID- 19	No	1893	0	1	4 9	33 52.8	1764	0 1	1 3	8	25	0.08	1711	0	1	3	8	23	0.08	129	3	13	28	44	113	3.53
	Cough	Yes No	933 2021	0	3 1 1	1 38 5 13	110 · 54 7.1		0 1	1 4 1 4	7.25	38 26	0.19	461 1646	0	1	3	7	21 23	0.51	433 312	8	18 16	37 32.5	65 58	155 133	0.64
	Fever	Yes No	805 2086	0	2	7 <u>22</u> 4 11	84 - 49 26.9	555 1834	0 1	1 3 1 3	8	30 26	0.22	526 1766	0	1	3	7	22 23	0.95	250 252	6.45 6	18 16	37 31.5	64.5 58	154.1 130.25	0.74
	Short of breath	Yes No	740 2166	0	3	9 32.25 4 12	102 - 53 13.1	430	0 1	1 <u>3.5</u> 1 3		25.55 26	0.42	406 1761	0	1	3	7	21 23	0.42	310 337	7	17.25 15	36 31	62.75 56	163.65 128.4	3.07
	Sore throat	Yes No	660 1713	0	3 7 1	5 29 5 14	99 - 62 0.2	435	0 1	1 4 1 4	8	30.6 30.6	0.03	411 1325	0	1	4	7	21 22	0.76	225 327	8	20 18	41 34	69 60.5	166 149.6	0.10
	Runny nose	Yes No	1113 2040	0	1	5 15 5 14	73 - 65 2.1	1386 878	0 1	1 4 1 3	8	26 - 27.15	3.09	847 1566	0	1	3	7	23 21	0.00	235 401	6 7	15 18	33 35	62.5 62	140.3 151	0.56
	Headache	Yes No	786 1514	0	2	6 <u>15</u> 4 11	69 -	1639 625	0 1	1 <u>3</u>	8	25.1 · 29	1.39	606 1267	0	1	4	8	25 24	0.13	161 197	7	15 16	31 32	58 53	138 109.4	1.01
	Muscle aches	Yes No	1312 1799	0	2 6	5 20 4 10	89 - 45 23.4	1317	0 1	1 <u>3</u> 14	8	26 - 27	1.03	905 1538	0	1	4	8	22 24	0.46	365 213	8	17	35 29	66 53	154.6 128.8	1.37
		Yes	1027	0	2	8 26.5	96 -	1586	0 1	1 3	7	26 -		634	0	1	4	8	22		349	7	18	37	66	152.6	
	Abnormal sense of smell	No Yes	2310 516	0 8.		4 10 3 53	40 91.8 138 -	678 2095	0 1	1 4 1 3	9	27 24 -	2.85	2031 141	0	1	3 4	7	22 30	0.51	215 347	5 8	15 18	29 38	51 66.5	125.9 145.4	2.46
	Abnormal sense of taste	No Yes	2289 537	0	1	4 10 2 49		169 2064	0 1	15	14	56.6 23 -	3.81	2002 170	0	1	3	7	22 31.1	0.23	225 337	5 7.8	15 18	29 38	51 65	127.4 144.4	2.36
	Fatigue	No Yes	1897 929	0	1	4 10	42 30.3	200	0 1	1 5	13 8	56.05 25 ·	0.51	1628 544	0	1	3	8	22.65 23.85	0.95	211 351	5	15 19.5	28 38	47 70	96.5 163.5	4.73
	Diarrhoea	No Yes	2431 395	0	1	5 14 7 24	62 4.3 92 -	578 1977	0 1	1 4	8	34.3 26 -	0.77	1897 275	0	1	3	7	22 24.3	0.14	454 108	6 11	16 21.5	33 41.5	59.75 71.5	139 162.8	1.64
	Nausea or Vomiting	No Yes	2581 245	0	1	5 14 7 23		287 2093	0 1	1 4	8	38.1	0.57	2007	0	1	3	7.5	23 21.8	0.34	488 74	7	17	33 37.5	60.25 69	142.6 141.35	0.38
	Chilblains	No Yes	2738 88	0		5 15 5 25.75	65 0.9		0 1	1 4		25.5 26.9 -	0.23	2112 60	0	1	3	8	23 21.2	0.81	535 27	6 12.2	16 28	33	61 80	139	1.22
Household symptoms	Cough in household	No Yes	2354 472	0		5 14 6 21	62 1.9 77 -	1929 335	0 1	1 4	8	26 31.3	0.20	1857 315	0	1	3	8	23	0.17	425	7	18	35	62 57	140.6	0.49
	Fever in household	No Yes	472 2125 701	0	1	5 14 6 18	65 1.3 73 -	335 1745 519	0 1	1 4	8	26 26 -	0.47	1678 494	0	1	3	8	24 21	0.16	13/ 380 182	6.05	16 17.75 16.25	31 34 33	63.25 56.5	146.6 144.1 138.45	0.24
	Short of breath in household		2431	0	1	5 14			0 1	. 3	8	26 -	0.22	1895	0	1	3	8	23	0.87	460	7	16.75	35	62.25	151.05	0.57
	a lon or or well in nousehold	No Yes	2431 395	0	2	5 14 6 18.5	65 1.4 74 -	293	0 1	. 3 1 4	8	26 32.4 -	0.22	1895 277	0	1	3	8	23	0.87	460 102	7 6.05	16.75 17.25	35 31	62.25 51.75	151.05 109.85	0.57
	Sore throat in household	No Yes	2074 752	0	1	5 14 5 15		1667 597	0 1	1 3	8	26.7 25 -	0.27	1593 579	0	1	3	8	23	0.83	407 155	7	16 18	33	60	130	0.64
	Runny nose in household	No	2339	0	1	5 15	67 0.3		0 1	1 3	8	25 -	1.37	1786	0	1	3		23	0.01	470	7	18	37	69	170.9	0.52
	Headache in household	Yes	487	0	2	5 13	63 -	395	0 1	1 4	8	25 -		1786 386 1605	0	1	4	8	24.75	0.01	92	7 6 6	13.75	31.5	61.75 60.25 58	175.8	
	- waddache in nousenoid	No Yes	2025 801	0	2	5 14 6 19	60 2.8 89 -	599	0 1	1 3 1 4	8	26 25.1 -	0.03	1605 567	0	1	3 4	8 7	24 20	u.54	360 202	8	16 19	32.5 37	58 71.75	130 164.5	1.65
	Muscle aches in household		2168 658	0	1	5 13	60 6.5	1800 464		1 3	8	25	0.33	1736 436	0	1	3	8	23 22.25	0.89	368 194	6	15.75 19	32.5 39		140.3	1.11
	Abnormal sense of smell in	Yes		0		7 23									0	1	4	7				8			63.75	153.7	
	household	No Yes	2582 244	0		5 13 5 44	60 18.3 125 -	2151	0 1	1 3 1 4	8	26 37.4 -	0.37	2068 104	0	1	3 4	8 7.25	22 32.4	0.73	431 131	6 8	17 16.5	34 36	60 65	138.5 203	0.24
	Abnormal sense of taste in household	No		-		5 13				1 3			0.77	2056	0	1	3	7	22	0.48	447	6	17.5	33	60	138	0.44
	Fatigue in household	Yes No	243 2264	0		2 39.5 5 13	62 3.6		0 1	1 4 1 3		37.65 - 25	0.41	116 1790	0	1	4	8	33.75 22	0.99	115 410	8	16 16	37 33	71 61	201.4 142.2	0.33
	Diarrhoea in household	Yes No	562 2604	0	2	7 22 5 15	79 - 65 0.4			1 4 1 3		35.1 - 26	0.42	382 2005	0	1	3	8	26.9 23	0.25	152 514	6.55 7	19 18	37 34	61.75 61	141.45 139	0.06
	Nausea or Vomiting in	Yes	222	0 1.		6 14		174		1 4		34.7 -		167	0	1	4	8	24.4		48	6	13	31.5	64.5	184.55	
	household	No Yes	157		2	5 15 5 14	59 -	126	0 1.25		7.75	23 -	0.30	2050 122	0	1 1.25	3 4	7.75 7.75	23 22.9	0.19	531 31	7	17.5 14	34 29	61.5 53	143 112.5	0.46
	Chilblains in household	No Yes	2785 41			5 15 5 31	66 0.1			1 3	8		0.25	2143 29	0	1	3	8	23 40	0.45	551 11	6.5 10	17 20.5	34 31	61 64.5	141.5 136.5	0.13
	Serostatus (Eurolmmun)	Confirmed positive (index >=1.1)		0	1	3 8		-										_					_		_		
	Serostatus (EuroImmun) in	Not confirmed positive (index < 1.1) Seronegative (index < 0.35)		0		3 8		1																			
	four strata	Weak reactivity (0.35 <= index < 1.1)				10 38		1																			
	Nete	Low level seropositive (1.1 <= index < 3) High level seropositive (index >=3)	160 402	4.9 7	15 28 18 3	.5 45 16 67	91 155]																			

 Low level serepositive (11 - on index < 3)</td>
 150
 4.9
 15
 28.5
 45
 91

 High level serepositive (Index >-0)
 402
 7
 18
 36
 67
 155

 Note:
 p-values are expressed as -log(10) values date to rand numbers. Values are ocloared ref of 900, represend arcs of 0.000, adjusted for having conducted 69 tests, using Bonterron's method. This corresponds to a -log(10) values of 0.000, adjusted for having conducted 69 tests, using Bonterron's method. This corresponds to a -log(10) value of 3.14

Table S7: Continuous exposure variables: primary and sensitivity analyses

Poisson regression modelling of the relationship between outcome and immunological correlates of protection. Cell values are incidence rate ratios with 95% confidence intervals. There is statistical evidence from likelihood ratio tests that models including a T cell number and antibody signal interaction term improve model fit over predictions of a model including antibodies alone (cells marked *). Correlates of protection are modelled as log transformed variables.

		del 1: dies only		del 2: Is only		del 3: and T cells		odel 4: ells and interaction
	Unadjusted	ed With adjustment Unadjusted With adjustment Unadjusted With adjustment for covariates for covariates					Unadjusted	With adjustment for covariates
log(Anti-Spike IgG antibody index)	0.57 (0.49, 0.66)	0.54 (0.46, 0.63)	N/A	N/A	0.58 (0.49, 0.68)	0.55 (0.46, 0.64)	1.10 (0.80, 1.51)	1.06 (0.76, 1.47)
Log(T-SPOT response to SNM pools)	N/A	N/A	0.77 (0.70, 0.84)	0.75 (0.69, 0.83)	0.97 (0.87, 1.09)	0.98 (0.87, 1.09)	0.49 (0.34, 0.70)	0.48 (0.33, 0.70)
Interaction	N/A	N/A	N/A	N/A	N/A	N/A	0.75 (0.65, 0.87)	0.75 (0.64, 0.87)
<i>p</i> -value from a likelihood ratio test, comparing model fit vs Model 1	N/A	N/A	N/A	N/A	0.60	0.68	0.0002 *	0.0002 *

Figures

Figure Legends

Figure S1: Outbreak in the UK and its relationship to follow-up

The outbreak kinetics in the UK, and its relationship to follow-up, are shown. Data is from coronavirus.data.go.uk.

Figure S2: Patterns of serological responses seen

The EuroImmun anti-Spike S1 IgG index is plotted against the Roche Nucleoprotein total antibody assay ratio. The manufacturer's recommended cutoffs are shown (1.0, 1.1 respectively), as is an exploratory cutoff for the EuroImmun assay (0.3, green line).

Figure S3: Correlations between responses to different SARS-CoV-2 components

Spearman correlation coefficients between the S1, S2, Nucleoprotein, Matrix protein, structural proteins and Envelope proteins, as well as anti-Nucleoprotein and S1 serological responses in 2,826 individuals from streams A,B and C.

Figure S4: SNM T-SPOT results compared with anti-Nucleoprotein antibody

SNM (Spike, Nucleoprotein and Matrix protein) responsive T cell numbers and their relationship to anti-Nucleoprotein serological responses in 2,672 from Streams A,B. (A) distribution of anti-N (Roche) serological assay index, and its relationship to symptoms. The vertical line is at 0.8, the manufacturer's 'borderline' cutoff. (B) bivariate plots of anti-N antibody responses and SNM T-SPOT results. The horizontal line corresponds to 12 spots / 250,000 cells. (C) distribution of SNM T-SPOT results. (D) As in B, but for Envelope and Structural proteins T-SPOT results; (E) distribution of Envelope and Structural (ES) T-SPOT results. In marginal histograms (A,C,E), the number of individuals reporting symptoms is depicted in red.

Figure S5: SNM responsive T cell numbers in individuals with previous positive PCR tests


SNM T-SPOT results and their relationship to anti-Spike S1 (EuroImmun) serological responses in 154 individuals with past SARS-CoV-2 infection from Stream C. (A) distribution of anti-Spike S1 (EuroImmun) serological assay index, and its relationship to symptoms. The vertical line is at 0.8, the manufacturer's 'borderline' cutoff. (B) bivariate plots of anti-S1 IgG responses and SNM T-SPOT results. The horizontal line corresponds to 12 spots / 250,000 cells. (C) distribution of SNM T-SPOT results. (D) As in B, but for Envelope and Structural (ES) proteins T-SPOT results; (E) distribution of Envelope and Structural (ES) T-SPOT results. In marginal histograms (A,C,E), the number of individuals reporting symptoms is depicted in red.


Figure S6: Selection of cohorts at high and low risk of previous SARS-CoV-2 infection

Selection of high SARS-CoV-2 and low SARS-CoV-2 infection risk cohorts (A). (B) SNM T-SPOT results in these populations; (C) anti-S1 IgG responses in these populations; (D) bivariate plot showing anti-S1 IgG responses vs. SNM T-SPOT results. The blue box depicts individuals with elevated (more than 12 cells per 250,000 PBMC) responses who are seronegative.

Figure S7: ROC analysis separating low risk individuals from those with past infection


Receiver-operator curves showing separation of 1,126 individuals at low risk from historical SARS-CoV-2 infection from 154 individuals with proven infection by (A) SNM T-SPOT results; (B) Envelope and Structural protein (ES) T-SPOT results.






	T-SPOT:Structural	T-SPOT:Envelope	T-SPOT:Spike S2	T-SPOT:Membrane	T-SPOT:Spike S1	T-SPOT:Nucleoprotein	Anti-S immunoassay	Anti-N immunoassay	1 1
T-SPOT:Structural	1	0.39	0.37	0.4	0.36	0.35	0.13	0.12	- 0.8
T-SPOT:Envelope	0.39	1	0.34	0.35	0.32	0.31			- 0.6
T-SPOT:Spike S2	0.37	0.34	1	0.56	0.58	0.59	0.39	0.37	- 0.4
T-SPOT:Membrane	0.4	0.35	0.56	1	0.6	0.61	0.4	0.38	- 0.2
T-SPOT:Spike S1	0.36	0.32	0.58	0.6	1	0.63	0.44	0.43	- 0
T-SPOT:Nucleoprotein	0.35	0.31	0.59	0.61	0.63	1	0.49	0.47	0.4
Anti–S immunoassay	0.13		0.39	0.4	0.44	0.49	1	0.51	0.6
Anti–N immunoassay	0.12		0.37	0.38	0.43	0.47	0.51	1	-0.8


Fig. S3







A Fire, Police and Healthcare worker staff reporting no COVID-19 related symptoms, no belief they had had COVID-19 nor any positive COVID-19 tests

В







Anti-Spike IgG confirmed positive (EuroImmun index >= 1.1)

